Navigation Links
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Date:8/8/2008

rite-down of our investment in Napo. This investment, which was funded by a milestone payment from Napo, was recorded as part of our agreement with Napo in 2007.

For the six months ended June 30, 2008, revenues totaled $5.0 million, up from $3.9 million in the first six months of 2007. Consistent with second quarter results, the increase was primarily attributable to a $3.0 million improvement in cost recovery from our EAP to treat patients with ALS in Italy. This was partially offset by the absence of license income from Napo and the revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our settlement agreement with Genentech Inc. and Tercica Inc. entered into in 2007.

The net loss for the six months ended June 30, 2008 was $9.5 million, or $0.08 per share, compared to $12.8 million, or $0.12 per share, for first six months of 2007. Year-over-year, R&D Expenses increased to $10.8 million for the first half of 2008, from $9.8 million, reflecting an increase in clinical trial activity for our FOB and IPLEX(TM) programs. SG&A Expenses fell to $3.0 million for the first half of 2008 from $6.5 million a year earlier due to the elimination of litigation expenses following the March 2007 settlement and the removal of commercial expenses associated with our business restructuring plan. The $446,000 loss on investments represents the write down on the Napo investment during the first half of 2008.

Interest income for the first half of 2008 was $375,000 and was a reduction from the $525,000 earned in the same period of 2007 due to the combination of a lower interest rate environment and a lower average cash balance. Interest expense increased to $682,000 in the most recent six month period from $306,000 during the corresponding period of 2007. The increase was due to an increase in the debt discount amortization resulting from the quarterly payment of our 2005 convertible notes, which began in March 2008. '/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... Bernd Eschweiler and Beate Kilb, Institute for Water Research, Schwerte, Germany , ... Introduction , Bacterial diversity in environmental ... of isolated strains. A problem for the analysis and , ... most of the bacteria species present in the sample. Therefore isolated ...
... , Tochigi Cancer Center, Tochigi, Japan , ... Introduction , Denaturing gradient gel electrophoresis (DGGE) ... scanning methods. It has evolved enormously over the last , ... A practical method on this topic has been reported recently. 1 The ...
... Ibrahim Buyuksal, and William S. Dalton,H. Lee Moffitt Cancer Center and Research Institute, ... , ... Identifying of mutations within specific genes has become an important , ... many diseases, , including cancer. Several ...
Cached Biology Technology:Microbial Diversity in Ground and Surface Water Analyzed by Denaturing Gradient Gel Electrophoresis Using the DCode System 2Microbial Diversity in Ground and Surface Water Analyzed by Denaturing Gradient Gel Electrophoresis Using the DCode System 3Microbial Diversity in Ground and Surface Water Analyzed by Denaturing Gradient Gel Electrophoresis Using the DCode System 4Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System 2Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System 3Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 2Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 3Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 4Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis 5
(Date:7/25/2014)... 1 (NRG1) is a pleiotropic factor characterized by ... splicing of exons that confer to the protein ... for both the myelination occurring during development and ... peripheral nerve: axon degeneration, axon regrowth, remyelination and ... Australia have discovered that the soluble NRG1 upregulation ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... evolutionary paradigm, Luiz Rocha and colleagues from the Smithsonian ... and the University of Hawaii, report coral reef fish ... than from fish thousands of miles away. An ecological ... development of a more synthetic treatment of speciation on ...
... the mouth and throat, surgery is a frequent ... swallowing dysfunction and external scarring. Researchers from the ... Otorhinolaryngology/Head and Neck Surgery, have completed two studies ... demonstrate the effective use of the daVinci Surgical ...
... of Medicine in St. Louis have learned that a ... successes in treating diabetic rats with embryonic pig tissues. ... surprised to find that they didn't have to give ... cell transplants. They had expected rats that received no ...
Cached Biology News:An (ecological) origin of species for tropical reef fish 2Penn Researchers Use Robotic Surgery 2Penn Researchers Use Robotic Surgery 3Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes 2Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes 3
... ESGRO Complete Derivation Kit is intended ... cells from delayed blastocysts in serum-free ... Clonal Grade ... Blastocyst Incubation Medium Trypsin Solution ...
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: